Swathi sri’s Post

𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 - 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐇𝐮𝐛 The bioinformatics services market is expected to grow to between $8.8 billion and $12.71 billion by 2031–2033 👉 ➡️ 𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑺𝒂𝒎𝒑𝒍𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 https://lnkd.in/dW-w4RYW #Bioinformatics, as associated with genetics and genomics, is a scientific subdiscipline that involves using computer technology to collect, store, analyze and disseminate biological data and information, such as #DNA and amino acid sequences or observations about those sequences. Bioinformatics services are critical in managing, analyzing, and interpreting vast amounts of biological data generated from genomics, proteomics, and other high-throughput experiments. These services leverage computational tools and algorithms to transform raw biological data into meaningful insights, enabling researchers to understand complex biological systems and make informed decisions. With the exponential growth of data from next-generation sequencing (NGS), bioinformatics services help streamline data processing, ensuring accuracy and efficiency in genomic analysis. 👉 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨 https://lnkd.in/danwfbTC One of the key areas where bioinformatics services are making an impact is drug discovery. By analyzing genetic data, bioinformatics can identify biomarkers and molecular targets that are essential for developing new therapeutics. This allows pharmaceutical companies to design more targeted drugs, improving the chances of successful treatments. In personalized medicine, bioinformatics plays a vital role in tailoring treatments to individual patients based on their genetic makeup, helping healthcare providers develop more precise and effective interventions. 🅺🅴🆈 🅼🅰🆁🅺🅴🆃 🅿🅻🅰🆈🅴🆁🆂- Siemens Healthineers | Stryker | Beckton | GE HealthCare | Teva Pharmaceuticals | Viatris | Ramsay Health Care | Labcorp | Baxter Pharmacy | Boston Scientific | Regeneron | #bioinformatics #genomicanalysis #computationalbiology #bigdata #biotech #drugdiscovery #personalizedmedicine #genomics #biologicaldata #nextgensequencing

𝐍𝐆𝐒 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 𝐚𝐧𝐝 𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬 The Next-Generation Sequencing (NGS) Informatics and Clinical Genomics Market focuses on tools, software, and services that analyze and interpret genomic data generated through NGS platforms. These solutions play a critical role in transforming raw sequencing data into actionable insights for diagnostics, precision medicine, drug discovery, and research. With the increasing adoption of NGS in clinical settings, the demand for robust informatics solutions that streamline workflows, manage large datasets, and deliver accurate results has surged. 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/dBth3iXB 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 Integration of AI and Machine Learning: Advanced algorithms are enhancing the speed and accuracy of genomic data interpretation. Cloud-Based Genomics Platforms: Cloud solutions offer scalable storage and real-time collaboration for large datasets. Increasing Use of Multi-Omics Data: Combining genomics with proteomics, transcriptomics, and metabolomics provides a comprehensive view of biological processes. Regulatory Compliance Tools: Informatics solutions tailored to meet regulatory standards like GDPR and HIPAA ensure secure and compliant data management. Focus on Whole-Genome and Exome Sequencing: Growing adoption of comprehensive sequencing methods increases the demand for robust informatics support. 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐁𝐮𝐲 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/dX_Z377b #Company 2bPrecise | EPIC Systems | Flatiron Health | GenomOncology | Illumina | IBM | Koninklijke Philips | QIAGEN | SOPHiA GENETICS   #Type LIMS Data Analysis Interpretation Tools Storage Computing Solutions   #Applications Academics and Research Institutes Biopharmaceutical Industry Diagnostic Industry Government Agencies Hospitals and Clinics #NGSInformatics,#ClinicalGenomics,#NextGenSequencing,#GenomicData,#PrecisionMedicine,#HealthcareInnovation,#Bioinformatics,#GenomicsResearch,#MarketTrends,#BiotechSolutions

🌟 Join us at the AI in Drug Discovery Xchange San Francisco 2024 for an exclusive session on September 26th, 2024! 📅 🚀 We're thrilled to present "Leveraging Machine Learning and Genomics in Target Identification and Validation to Tackle Complex Disease Mechanisms," featuring industry expert Christopher Yohn, Ph.D., Executive Director at TRexBio 💡 Christopher spearheads the development of TRexBio's Deep Biology platform, contributing to therapeutic programs, indication selection, and translational projects. With a background in biotechnology and bioinformatics, Christopher brings a wealth of expertise from companies like UNITY Biotechnology and Sapphire Energy. Discover key strategies for: 🔬 Implementing ML for diverse molecular profiles and disease subtypes 🧬 Using genomic data to refine target strategies 🤝 Collaborating for translational potential 🔍 Validating ML-driven predictions in models and trials 🚀 Future directions for ML and genomics in drug discovery 📅 Date: September 26, 2024 🕘 Time: 09:05 - 10:05 📍 Location: DoubleTree by Hilton, San Francisco Airport, Burlingame, CA Register now to secure your seat and join us in advancing healthcare through AI-driven insights! 📌 https://lnkd.in/eDEE7DCZ 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AIinDrugDiscovery #MachineLearning #Genomics #Bioinformatics #Biotechnology #Pharmaceuticals #HealthcareInnovation #TargetIdentification #Validation #TranslationalMedicine #ClinicalTrials #DataScience #ComputationalBiology #PrecisionMedicine #InnovationInHealthcare #Bioinformatics #Biotech #Pharma #SanFranciscoEvents #HealthTech #ResearchAndDevelopment #MedicalResearch #TherapeuticDevelopment #DrugDevelopment #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆: 𝗛𝗮𝗿𝗻𝗲𝘀𝘀𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗕𝗲𝘁𝘁𝗲𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗚𝗲𝘁 𝗣𝗗𝗙 𝗦𝗮𝗺𝗽𝗹𝗲: https://lnkd.in/dJCBK23C 𝗨𝗻𝗹𝗼𝗰𝗸 𝗮 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗲𝘅𝗽𝗲𝗿𝘁 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗗𝗙 𝘀𝗮𝗺𝗽𝗹𝗲—𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲𝗹𝘆 𝗳𝗼𝗿 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗲𝗺𝗮𝗶𝗹 𝗵𝗼𝗹𝗱𝗲𝗿𝘀. 📧 The field of drug discovery is on the brink of transformation, driven by breakthroughs in technology and a deeper understanding of human biology. Advances in artificial intelligence, machine learning, and bioinformatics are accelerating the discovery process, reducing time and cost to bring life-saving medications to patients. As we harness these powerful tools, the path to targeted, effective treatments has never been clearer, promising a future where we can combat complex diseases more efficiently than ever. Precision medicine is also reshaping drug discovery by enabling researchers to develop therapies tailored to individual genetic profiles. This approach is not only enhancing drug efficacy but also reducing the risk of adverse effects, making treatment safer and more effective. With the integration of genomics, data analytics, and biotechnology, the next generation of drugs has the potential to revolutionize patient care on a global scale The future of drug discovery will rely heavily on collaboration between pharmaceutical companies, tech innovators, and healthcare providers. By working together, these industries can overcome the challenges of complex diseases, ultimately improving patient outcomes. As we look ahead, the commitment to innovation and shared knowledge will be essential in creating a healthier, more hopeful future. #DrugDiscovery #HealthcareInnovation #AIinMedicine #PrecisionMedicine #Pharmaceuticals #FutureOfHealth #Biotech #LifeSciences #InnovationInHealthcare #ClinicalResearch

Why Biotech now? Together with Piotr Karwatka, we have recently been exploring the broad field of bioinformatics and the healthcare industry. There are many reasons to invest in this space now, and here are some of them, based on a recent article I read last week: AI-based methods could double the productivity of R&D in Pharma. In May 2024 AlphaFold 3, expanded its capabilities from proteins to other molecules that make up living things: proteins, DNA, RNA, and small molecules called ligands. Such models are changing drug development by reducing months of trial-and-error experiments to just hours of computation. Real case study: Insilico, a startup that uses AI to develop drugs, says its software identified a new drug target and designed a molecule suitable for human trials in only 18 months and at a cost of $2.7m—a fraction of the usual time and expense required. BCG estimates that about 65 AI-inspired molecules are currently in human trials. AI is already helping pharmaceutical companies make smarter choices about which molecules to take forward. Reducing failures in phase-two trials by just 20% could save nearly $450m on a single drug’s development. Source: THE ECONOMIST MAGAZINE - 2024 SPECIAL ISSUE - THE WORLD AHEAD 2025

#Computer_aided_Drug_Design: (Computational Drug Design) 🔅Computational Drug Design (CDD) is revolutionizing drug discovery by making the process faster, cost-effective, and precise. With cutting-edge tools and data-driven methods, researchers are uncovering innovative drug candidates like never before. ✴️What is Computational Drug Design? 🧪 CDD leverages computational tools to design and optimize drug candidates. Unlike traditional trial-and-error approaches, it uses simulations and algorithms to predict molecular interactions and biological behaviors. ⏺️Key Methods in CDD and Their Tools 1️⃣ Structure-Based Drug Design (SBDD) Focuses on the 3D structure of target proteins to study how small molecules bind to active sites. 🔧Tools: AutoDock, Schrodinger’s Glide, GOLD, PyMOL. 2️⃣ Ligand-Based Drug Design (LBDD) Relies on known molecules that interact with targets to identify and optimize new drug candidates. 🔧Tools: ChemAxon, MOE, Pipeline Pilot, OpenEye ROCS. 3️⃣ Virtual Screening Screens large chemical libraries to identify promising leads. 🔧Tools: ZINC Database, Schrödinger’s Maestro, OpenEye QUACPAC, KNIME. 4️⃣ De Novo Drug Design Creates new molecules from scratch tailored to specific biological targets. 🔧Tools: Schrodinger’s Maestro, DeepChem, REINVENT. 5️⃣ Molecular Dynamics (MD) Simulates the physical movements of atoms and molecules over time to study stability and binding affinity. 🔧Tools: GROMACS, AMBER, CHARMM, NAMD. 💻The Role of AI and Machine Learning: ⏩AI and ML are game-changers in drug design, helping researchers predict biological activity, analyze massive datasets, and even generate new molecules. These technologies are enabling smarter and faster decision-making. 🔧Tools: TensorFlow, PyTorch, DeepChem, AlphaFold, Chemprop. 🌟Why CDD Matters ? -#Efficiency: Reduces time and cost in drug discovery. 🔧Tools: KNIME, Pipeline Pilot. - #Precision: Predicts molecular interactions accurately. 🔧Tools: Schrodinger’s Glide, MOE, AutoDock. -#Safety: Evaluates ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties early. 🔧Tools: SwissADME, ADMET Predictor, StarDrop. - #Personalized_Medicine: Supports the creation of tailored treatments. 🔧Tools: PolypharmDB, MatchMaker, PharmMapper. ✴️Real-World Applications: 📌 Drug Repurposing: Identifies new uses for existing drugs. Tools: DrugBank, CANDO, DrugCentral. 📌 Biologics Design: Optimizes monoclonal antibodies and peptides. Tools: Rosetta, Pymol, BioLuminate. 📌 Clinical Trials: Improves trial design by predicting drug behaviors. Tools: SimCYP, GastroPlus, SAS Clinical. 🌟The Future of CDD: With the integration of AI, ML, and advanced computational techniques, CDD is unlocking new possibilities. From designing treatments for rare diseases to improving drug safety, the future is exciting. Are you leveraging computational tools in your projects?

🚀 𝐄𝐦𝐩𝐨𝐰𝐞𝐫 𝐘𝐨𝐮𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐰𝐢𝐭𝐡 𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 Transform your raw genomic data into actionable insights with AGTC Genomics' Bioinformatics Services—tailored to meet your unique research needs. Whether you are exploring oncology, microbiomes, or drug discovery, our expertise ensures seamless integration from experiment planning to data interpretation. 🌟 𝐖𝐡𝐲 𝐂𝐡𝐨𝐨𝐬𝐞 𝐀𝐆𝐓𝐂 𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬? ✔Customized Solutions: Tailored bioinformatics support for diverse scientific projects. ✔Cutting-Edge Technologies: Utilize advanced sequencing, data analysis tools, and proprietary pipelines. ✔Wide-Ranging Expertise: Comprehensive services spanning genomics, transcriptomics, epigenomics, and more. ✔Dedicated Project Management: PhD-level experts guiding your project from start to publication. 🔬 𝐎𝐮𝐫 𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞 ● Genomic Data Analysis: GWAS, de novo sequencing, and structural variant calling. ● Metagenomics & Microbiome Analysis: Pathogen surveillance, AMR monitoring, and environmental studies. ● Epigenomics & Methylation Analysis: DNA methylation profiling, ATAC-seq, and bisulfite sequencing. ● Transcriptomic Analysis: Whole transcriptome sequencing, mRNA-Seq, and small RNA analysis. 🧬 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 ● Fast Turnaround: Timely data analysis with publication-ready results. ● Scalable Solutions: Ideal for academic, biotech, and pharmaceutical projects. ● Post-Project Support: Assistance with publications and further research. ● Seamless Communication: Direct access to our bioinformatics team for smooth project execution. 💡 From data to discovery, AGTC Genomics empowers your research with precision and reliability. Collaborate with us and experience bioinformatics as a service—designed to unlock new scientific breakthroughs. 📧 info@agtcgenomics.com 🌐 www.agtcgenomics.com hashtag #Bioinformatics hashtag #GenomicData hashtag #MicrobiomeResearch hashtag #PrecisionMedicine hashtag #DataDrivenResearch hashtag #AGTCGenomics hashtag #BigDataInScience hashtag #ScientificBreakthroughs

🌕 From Data to Drugs: The Role of Artificial Intelligence in Drug Discovery By Wyss Institute at Harvard University 💊This terrific newsletter details new ways #AI can drive drug development in a seemingly democtratic manner, as opposed to traditional drug discovery that is “slow, expensive, and prone to high clinical failure rates due to poor safety profiles, lack of efficacy, or both.” 💊 A big shoutout to the authors Milad Alucozai William Fondrie and Megan Sperry for this outstanding piece! Following are a few excerpts from their “Code to Cure” newsletter: 💊 “In silico drug discovery provides an opportunity to impact spaces beyond traditional small-molecule drugs in the largest disease markets. As mentioned, #AI is used to design larger molecules, which account for an increasing proportion of FDA-approved medicines and a larger market share than small molecules. Further, biologics are particularly well suited to AI-augmented development due to the many physicochemical properties that must be optimized, creating a highly complex and multidimensional search space. The critical technical considerations for machine learning in biologics are well-reviewed here.” 💊“With the dawn of these new technologies, we are poised to chart new territories that help get medicines into the hands of patients faster than ever before.” —David Reese, M.D., CTO AMGEN 💊“Imagine a #biotech company leveraging a specialized LLM for drug discovery alongside another for clinical trial analysis, combining their strengths for a more comprehensive approach.” 💊This shift opens doors for #startups to thrive in the #LLM space. Rather than engaging in a costly arms race to build the most significant model, they can focus on developing #targeted #LLMs that excel in #niche #applications. This could involve creating models optimized for analyzing genomic data, predicting protein structures, or generating personalized treatment plans. By leveraging existing hyper-scale models for general tasks and augmenting them with their specialized LLMs, startups can deliver unique value and drive innovation in the biotech industry without excessive spending on training and infrastructure.” 👉https://lnkd.in/ePXzCGuF #ai #machinelearning #llms #bioinformatics #efficacy #computerscience #drugs #drugdiscovery #future #oersonalized #innovationn #medtech #data #science #biotech #healthtech #digitalhealth #lifesciences #futureofhealthcare

#Precision #Medicine #Software Market Size, Share & Trends Analysis Report By Delivery Mode (On-premise, Web & Cloud-based), By Application (Oncology Pharmacogenomics, Other Applications), By End User (Healthcare Providers, Research & Government Institutes, Pharmaceutical & Biotechnology Companies), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028. 👤IMIR Market Research Pvt. Ltd.👤 📚𝐆𝐞𝐭 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐭 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐏𝐫𝐢𝐜𝐞:📝👇https://lnkd.in/dhMEs3ZP Applications: The software is used across various applications including drug discovery, clinical decision support, genetic analysis, and patient monitoring. It helps healthcare providers make informed decisions by integrating and analyzing complex data from multiple sources. Technological Advancements: The market is driven by innovations such as artificial intelligence (AI), machine learning, and big data analytics, which enhance the ability to analyze large datasets and identify patterns that can be used to predict patient responses to treatments and improve clinical outcomes. 📚𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐨𝐜𝐮𝐬𝐞𝐝 𝐎𝐧 𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬:👇 4D Path AB-BIOTICS Abbott AIRAmed GmbH Altis Labs Anumana Ardigen Aroko Bio Engineering BASE10 Genetics Beckman Coulter Life Sciences Biohope Biomedical Data Science Lab, GCUF Biorithm BioSymetrics Clarix Imaging Closed Loop Medicine Congenica CureMatch, Inc. domo.health Eli Lilly and Company Elucid Embleema Emulate, Inc. Roche Fabric Genomics Fabric Genomics Foundation Medicine Future Fertility Genedata Genialis Genomics plc Health Care Systems GmbH Human Longevity, Inc. i.e. healthcare #Intellectualmarketinsightresearch #Marketresearchreports #Size #Share #Trends #Growth #Opportunity #Outlook #Forecast #Covid19 #Segments #KeyPlayers #RegionsOutlook #GrowthPotential #PriceTrends #CompetitiveMarket #Forecast #2022o2028

Exciting update: we have announced AlphaFold 3 AI. Why this is important 👇 Enhanced Molecular Prediction: AlphaFold 3 predicts the structure and interactions of all life's molecules, including proteins, DNA, RNA, ligands, and more, with unprecedented accuracy. Improved Interaction Accuracy: For protein interactions with other molecule types, AlphaFold 3 offers at least a 50% improvement over existing methods, and doubles the accuracy for some critical interactions. Transformative Potential for Science and Medicine: The model aims to deepen our understanding of biological processes and significantly advance drug discovery efforts. Accessibility for Researchers: AlphaFold 3's capabilities are largely accessible for free via the AlphaFold Server, providing an essential tool for scientific research. Drug Design Innovation: AlphaFold 3 is utilized by Isomorphic Labs in collaboration with pharmaceutical companies to accelerate drug design, potentially leading to new treatments for various diseases. Foundation in AlphaFold 2: Building on the breakthroughs of AlphaFold 2, this version extends its scope beyond proteins to a wide range of biomolecules, enhancing its utility in scientific research and application. Global Accessibility and Educational Support: The AlphaFold Server is a free platform for non-commercial research worldwide, supported by educational resources to foster wider adoption and innovation. Empowering Rapid Scientific Advancements: By making detailed molecular interactions easily accessible, AlphaFold 3 enables faster hypothesis testing and could reduce the time and cost typically associated with experimental protein-structure prediction. Responsible Development and Deployment: DeepMind has engaged with domain experts to assess the impacts and potential risks of AlphaFold, ensuring its responsible use in the scientific community. Broad Implications for Biology:AlphaFold 3 helps reveal complex cellular mechanisms and interactions, offering insights that could lead to improved agricultural crops, enhanced understanding of diseases, and novel therapeutic strategies.